- Home
- ASPI vs SLS Comparison
ASPI vs SLS Comparison
Compare ASPI & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASPI | SLS |
|---|---|---|
| Founded | 2021 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 783.1M | 924.5M |
| IPO Year | 2022 | 2007 |
Fundamental Metrics
Financial Performance| Metric | ASPI | SLS |
|---|---|---|
| Price | $5.05 | $13.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $12.00 | $10.00 |
| AVG Volume (30 Days) | 4.7M | ★ 10.0M |
| Earning Date | 04-10-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $23,849,000.00 | N/A |
| Revenue This Year | $68.41 | N/A |
| Revenue Next Year | $126.69 | $110.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 475.48 | N/A |
| 52 Week Low | $3.92 | $1.39 |
| 52 Week High | $14.49 | $15.88 |
Technical Indicators
Market Signals| Indicator | ASPI | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 34.91 | 64.11 |
| Support Level | $3.98 | $3.91 |
| Resistance Level | $6.02 | N/A |
| Average True Range (ATR) | 0.62 | 1.39 |
| MACD | -0.21 | 0.40 |
| Stochastic Oscillator | 2.21 | 70.99 |
Price Performance
Historical ComparisonAbout ASPI ASP Isotopes Inc.
ASP Isotopes Inc is a materials company focused on producing and commercializing enriched isotopes for the nuclear medicine, healthcare, green energy, and quantum computing industries. Currently, the company has three operating segments: (i) nuclear fuels, (ii) specialist isotopes and related services, and (iii) construction services. Using proprietary technology-the Aerodynamic Separation Process (ASP)-the company enriches isotopes in South Africa, targeting high-value, low-volume markets to reduce reliance on foreign supply chains. Geographically, the company operates in South Africa, Hong Kong and United States generating key revenue from the Hong Kong region.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.